These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20381875)

  • 1. Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.
    Caligiuri MP; Teulings HL; Dean CE; Niculescu AB; Lohr JB
    Psychiatry Res; 2010 May; 177(1-2):77-83. PubMed ID: 20381875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
    Caligiuri MP; Teulings HL; Dean CE; Niculescu AB; Lohr J
    Hum Mov Sci; 2009 Oct; 28(5):633-42. PubMed ID: 19692133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia.
    Caligiuri MP; Teulings HL; Dean CE; Lohr JB
    J Clin Psychopharmacol; 2015 Apr; 35(2):168-74. PubMed ID: 25679121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.
    Caligiuri MP; Teulings HL; Filoteo JV; Song D; Lohr JB
    Hum Mov Sci; 2006 Oct; 25(4-5):510-22. PubMed ID: 16647772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nature of bradykinesia in schizophrenia treated with antipsychotics.
    Caligiuri MP; Teulings HL; Dean CE; Lohr JB
    Psychiatry Res; 2019 Mar; 273():537-543. PubMed ID: 30710809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
    Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapyramidal side-effects of antipsychotics in a randomised trial.
    Miller DD; Caroff SN; Davis SM; Rosenheck RA; McEvoy JP; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
    Br J Psychiatry; 2008 Oct; 193(4):279-88. PubMed ID: 18827289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
    Barnes TR; McPhillips MA
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
    Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
    J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinematic analysis of handwriting movements in patients with obsessive-compulsive disorder.
    Mavrogiorgou P; Mergl R; Tigges P; El Husseini J; Schröter A; Juckel G; Zaudig M; Hegerl U
    J Neurol Neurosurg Psychiatry; 2001 May; 70(5):605-12. PubMed ID: 11309453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrapyramidal motor abnormalities associated with late-life psychosis.
    Caligiuri MP; Lohr JB; Panton D; Harris MJ
    Schizophr Bull; 1993; 19(4):747-54. PubMed ID: 7905662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia.
    Fervaha G; Agid O; Takeuchi H; Lee J; Foussias G; Zakzanis KK; Graff-Guerrero A; Remington G
    Schizophr Res; 2015 Feb; 161(2-3):351-6. PubMed ID: 25471015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH; Byun HJ
    Clin Neuropharmacol; 2003; 26(6):312-6. PubMed ID: 14646611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.
    Pierre JM
    Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
    Inada T; Beasley CM; Tanaka Y; Walker DJ
    Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?
    Weiser M; Shneider-Beeri M; Nakash N; Brill N; Bawnik O; Reiss S; Hocherman S; Davidson M
    Schizophr Res; 2000 Dec; 46(2-3):81-9. PubMed ID: 11120419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.